医药行业周报：诺华放射性疗法Pluvicto在华申报上市

Investment Rating - The report does not provide specific ratings for the chemical pharmaceuticals and traditional Chinese medicine sectors, while the biopharmaceutical sector is rated as Neutral [1][7]. Core Insights - The pharmaceutical sector experienced a decline of 1.17% on November 13, 2024, underperforming the CSI 300 index by 1.79 percentage points, ranking 30th among 31 sub-industries [3]. - Notable performers within the pharmaceutical sub-industries included medical equipment (-0.13%), blood products (-0.37%), and vaccines (-0.41%), while offline pharmacies (-3.21%), hospitals (-2.34%), and medical research outsourcing (-2.27%) lagged behind [3]. - The top three gainers in individual stocks were TuoJing Life (+20.01%), SaiLi Medical (+10.06%), and QiDi Pharmaceuticals (+8.25%), whereas the largest decliners were ChangYao Holdings (-10.32%), LuKang Pharmaceuticals (-8.91%), and SiHuan Bio (-8.19%) [3]. Industry News - On November 13, 2024, Novartis' radioligand therapy Pluvicto received acceptance for its new drug application in China. This therapy targets PSMA and is linked to the radioactive isotope 177Lu, previously approved by the FDA in March 2022 for prostate cancer treatment [4]. - SaiLong Pharmaceuticals announced that its subsidiary received approval for the registration of Pregabalin capsules from the National Medical Products Administration [4]. - BuChang Pharmaceuticals reported that its subsidiary received a clinical trial acceptance notice for Compound Sodium Sulfate Tablets, intended for bowel cleansing before colonoscopy [4]. - Prolo Pharmaceuticals announced that its subsidiary received approval for the listing of Mesylate Previr raw materials from the National Medical Products Administration [4]. - China Medical announced that its subsidiary received a supplementary approval notice for injectable Cefazolin Sodium, which passed the consistency evaluation for generic drug quality and efficacy [4].